For manufacturers

Why manufacturers come to us

Most export failures are decided before the first shipment.

Not by the product, and rarely by the price. By choosing a market on a brochure, a partner on whoever answered the email, and a registration pathway after the product was already picked.

Partner The distributor was chosen because they replied

Responsiveness at the enquiry stage tells you nothing about whether a company sells your category, calls on the right prescribers, or already carries three competing lines it would rather push.

Evidence The market was assessed from a catalogue

Whether a molecule is crowded or wide open is a fact sitting in the national register. Entering without reading it is how a company files into a category with forty suppliers and misses the one next door with none.

Sequence Registration is discovered, not planned

The product is chosen, then the pathway is investigated. Reversed, whole categories open up that looked closed — and the dead ends are spotted before money moves.

Control After the agency is signed, visibility stops

Orders arrive or they do not, and nobody can tell you why. Who registered against you, what the shelf price became, whether the distributor is still pushing the line — all of it goes dark.

What we run

Eight functions, from first market read to steady reorders.

We are your commercial and regulatory arm in these markets, not a broker who makes an introduction and disappears. Everything below is work our team carries out on your portfolio.

01

Finding great distribution partners

We do not send you a directory. Every distributor in our markets is profiled from the register itself — what they actually hold, in which categories, from which manufacturers — so a shortlist is built on evidence rather than on who has a website.

Ranked by real portfolio overlap with your products
Category strength and national standing, not self-description
Who they already represent, and where you would conflict
Warm introduction and negotiation support through to agency

02

Building and analysing your portfolio

Which of your existing products belong in which market, in what order, and what you should add. We map your catalogue against each market's register and essential medicines list and rank it by what is genuinely open.

Your lines scored per market on supplier depth and demand
The thin positions where you would set price rather than match it
Gaps worth developing, with the volume signal behind each
Products to leave out, and the reason, in writing

03

Regulatory checking and registration

Site registration, product dossier, pathway and timeline — established before you commit, then carried through to submission. In several of our markets the plant must be approved before a single product can be filed, and that order catches people out.

Country-by-country route, requirement and realistic timeline
Dossier compiled, gaps in your existing pack identified early
Zone IVb stability and labelling requirements checked up front
Agency documentation, legalisation and filing handled locally

04

Quality and compliance

Buyers in these markets are increasingly unwilling to take a GMP certificate on trust, and regulators are tightening. We make sure what you present stands up before it is in front of either.

GMP, CPP and certification pack reviewed against each market's rules
Animal-origin, halal and excipient declarations prepared where required
Batch documentation and CoA formats aligned to local expectations
Queries from the regulator handled rather than forwarded

05

Pricing and positioning

What a line can actually be sold for, per market, per pack — taken from registered prices and from what competing products are really quoting, not from a target margin worked backwards.

Landed and shelf price benchmarks against real competitors
Where you hold leverage and where you would be undercut
Pack and presentation choices that change the price bracket
Tender and institutional pricing where the market is programme-led

06

Sales and marketing growth

A registration is not a sale. We work with the distributor after launch on the things that decide whether your line moves: who is detailing it, to whom, with what, and against what.

Launch planning with the distributor's own sales team
Promotional material and product training prepared locally
Target prescriber and institution mapping by geography
Reorder tracking, with the diagnosis when a line slows

07

Market and demand intelligence

The same engine we run for distributors, pointed at your side of the table. What is being granted, to whom, in your categories — every week, per market.

New registrations in your categories, and who took them
Competitors entering or lapsing out of a molecule
Essential medicines list changes and procurement signals
Renewal dates tracked ahead of the deadline, not after it

08

Account management and reporting

One point of contact for every market, and a written view of what happened in each one. You should not have to chase four distributors in three time zones to know how your export business is doing.

Weekly written reporting per market
Order, stock and reorder visibility from the distributor side
Quarterly review of what to push, fix or drop
Escalation handled by us, in market, in person where needed

And the part that is not a feature

We are on the ground, and we are accountable for the outcome.

A broker earns on the introduction and has no stake in what happens next. We earn when your product actually sells, which means our interest and yours point the same way from the first call. If a line is not going to work in a market, you will hear that from us early — it costs us less than selling you a year of effort that goes nowhere.

What this looks like in practice

Twelve ophthalmic products. No supplier in the country.

Reading one market's full register against its national essential medicines list, we found twelve ophthalmic molecules with no human-medicine registration in the country at all — not a thin market, an empty one. Glaucoma drops, diagnostic mydriatics, topical anaesthetics, an antifungal for a condition that blinds people there every year.

Weeks earlier, one of the larger distributors in that market had asked us for one of those twelve by name, unprompted. Demand on one side, nothing registered on the other, and no way for either party to see the other without reading 9,000 certificates line by line.

For a manufacturer with a sterile ophthalmic line, that is not a lead. It is a category with no incumbent to displace and a buyer already asking. That is the kind of position we are looking for on your portfolio.

Essential medicines cross-referenced664

Ophthalmic molecules with no supplier12

Registered in the country0

Where we place product

Seven markets, read properly rather than listed.

We work where we can actually do the regulatory and commercial work ourselves, with partner offices in Lahore, London and Almaty. If your market is not one we cover, we will say so on the first call rather than learn it with your money.

East Africa

Tanzania, Kenya and neighbours. Register-led, tender-heavy, and the market we know in the most depth.

Sudan and the Horn

Site registration before product registration, a large import dependency, and an established South Asian supply route.

Central Asia

Reached through our Almaty office, with different documentation norms and a very different competitive set.

Selected Asian and MENA markets

Taken on where a molecule, a certification or an existing relationship makes the route real.

Exporting from

Want to export from Bangladesh, Turkey, Pakistan or Egypt?

Those are the plants we work with every day, and we connect them to markets globally. We already know which of your products will clear registration in which country, who will actually sell them once they land, and what they can be sold for. One conversation is enough to find out whether your portfolio has a route worth taking.

BangladeshTurkeyPakistanEgyptElsewhere — ask us

Book a call Message on WhatsApp Twenty minutes, no preparation needed. Bring your product list.

Control

Who holds the registration?

It is the question that decides everything else, and it is usually left until the paperwork is already in front of you. Here is the plain version before you ask.

Stays yours You

The product, the dossier, the plant and the brand are yours throughout. Nothing in how we work changes that, in any market.

The part that matters The registration holder

In most of our markets the certificate names a local party, and whoever is named controls that product on the ground. Who it should be differs by country — and it is decided before filing, not after.

Replaceable Your distributor

Stocks it, sells it, details it. If they stop performing they can be changed — provided the step to their left was set up with that in mind.

The registration never goes in Nazryx’s name. We are your agent, not a party that holds your product hostage. Before anything is filed we tell you who should hold it in that market, and exactly what changing partner would involve later.

The output

What comes back, and how it reads.

Everything we run produces one working document per market: what is open, who could sell it, what the registration route looks like and what it is worth. Written to be acted on, not filed.

The section headings are below. What sits under them belongs to the company it was written for, so ask and we will walk you through a real one.

Ask for a sample

Market readConfidential

01

The market, honestly assessed

02

Your portfolio ranked against it

03

Distributor shortlist, with why

04

Registration route and timeline

05

Pricing position per line

06

What we would do next

Prepared for one manufacturer. Not circulated.

The partnership

What we are on the hook for.

Handing your products to an agent is an act of trust. These are the things we will put in writing before you do it.

No competing line in your category

We will not represent a directly competing product in the same category in the same market. You are not one of four names in a folder.

The registration never goes in our name

We are your agent, not a party holding your product. Who should hold the certificate in each market is settled with you before anything is filed.

We tell you when not to enter

If a market is crowded or the economics do not work, you hear that before you pay for a dossier. It costs us less to say so than to run a filing that leads nowhere.

Your documentation stays yours

Portfolio, pricing and certification pack stay confidential and stay in your control. If we part ways, nothing of yours stays behind with us.

Omar NazirPrincipal Director, Nazryx — these are commitments, not preferences.

How it starts

You will see the market read before you commit to anything.

The first piece of work is evidence, not a contract. If the register says your products are walking into a crowded category, you should know that before you have paid for a dossier.

Before we start

A scoping call

Twenty minutes on your portfolio, your certifications and which markets you are curious about. If we are not the right fit we will say so on the call rather than after an invoice.

Week 1

We load your portfolio

Product list, dosage forms, certifications, existing export markets and any registrations you already hold. Mostly exports you already have; none of it needs tidying first.

Weeks 2–3

The market read

Your catalogue against the register and essential medicines list of each target market: what is open, what is crowded, what the registration route and timeline looks like, and what it is worth.

Weeks 3–5

The distributor shortlist

Named companies ranked on portfolio fit and category standing, with what they already carry and where you would conflict. Introductions made and negotiations supported by us.

From week 5

Registration and launch

Dossier compiled, filing run in market, and the launch worked with the distributor's sales team once approval lands. Weekly reporting runs from here on.

Fit

We would rather say no early.

We take on a small number of manufacturers because each one means real regulatory and commercial work in market. It is worth being direct about where this fits and where it does not.

This works well if you

Manufacture finished pharmaceuticals to a recognised GMP standard
Want to enter or grow in African, Asian or Middle Eastern markets
Have a real portfolio — enough lines that which ones to push actually matters
Can support registration with a dossier and the documentation behind it
Would rather have one accountable partner than five distributors you cannot see

This is the wrong fit if you

Want a list of buyer contacts to email yourself — we represent, we do not sell leads
Need a single container moved once, with no interest in the market after it
Cannot share your product list and certifications — without them the read is generic
Are looking for someone to take your existing distributor relationship and simply re-paper it

Questions

The things manufacturers ask on the first call.

Are you an agent, a consultant, or a distributor?

We act as your trade and regulatory arm in the markets we cover. We do not buy and resell your product, and we do not take title to stock. We find and manage the distributor who does, and we run the registration and market work around it.

In practice that means you get the control of a direct relationship with the distributor, and we are the party accountable for the market working.

How are you paid?

Commission on business that actually moves, agreed per market before anything starts. Where a registration programme requires sustained regulatory work ahead of any revenue, that is scoped and agreed separately — we will not dress up a year of filing work as free.

What we will not do is charge for an introduction. If nothing sells, we have not earned.

We already have a distributor in that market.

Then the useful question is whether they are the right one, and that is answerable from the register rather than from the relationship. We can show you where they actually rank in your categories, what else they carry, and whether your line is a priority for them or a shelf filler.

Often the answer is that the distributor is fine and the problem is elsewhere — pricing, registration timing, or nobody detailing the product. We would rather fix that than replace them.

How long does registration actually take?

It varies by market and we will give you a real number per country rather than an average. What is consistent is the sequence: in several of our markets the manufacturing site has to be registered before any product from it can be filed, so a plant that is not yet approved is the first thing to fix, not the dossier.

We tell you the route and the timeline before you spend anything on it.

What do you need from us to start?

Your product list with dosage forms and strengths, your GMP and certification pack, the markets you already export to, and one person we can ask questions of. That is enough for the market read.

Dossiers and legalised documents come later, and only for the products you decide to take forward.

Start with the market read.

Send us your product list and tell us which market you are curious about. We will come back with what is open, what is crowded, and which distributors would actually sell it — before either of us talks about an agreement.

Book a call with us Email instead Nazryx — a company of Nazir & Company International (PVT) Limited

Your products, in markets that already need them.